Skip to main content

Letter to FDA on OxyContin Labeling Change


10.14.20

Excerpt: “Thus, this additional context and customary data standardization should be taken into account in assessing the potential role the 2001 label change had on the opioid epidemic. Studies, documents, and other data support these concerns related to higher dosage and longer duration in oxycodone prescribing (including OxyContin prescribing) that contributed to the opioid crisis,” wrote Walden, Guthrie and Griffith.

CLICK HERE to read the letter to FDA.

Letter